Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.

https://www.globenewswire.com/en/news-release/2021/05/20/2233198/0/en/Cybrexa-Therapeutics-Appoints-Stephen-Basso-as-Chief-Financial-Officer.html